Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Monogue, Marguerite L ^a   Nicolaua, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Cefepime; Ertapenem; ESBL; Escherichia coli; Levofloxacin; Urinary tract infection

Indexed keywords

CEFEPIME; CYCLOPHOSPHAMIDE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; URANYL NITRATE; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BROTH DILUTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; ESCHERICHIA COLI; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINARY TRACT INFECTION; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECT; ESCHERICHIA COLI INFECTION; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; UROPATHOGENIC ESCHERICHIA COLI;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; LEVOFLOXACIN; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 85032503606     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01329-17     Document Type: Article

References (14)

1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269 –284. https://doi.org/10.1038/nrmicro3432.
2. Cantón R, Valverde A, Novais A, Baquero F, Coque T. 2007. Evolution and current situation of ESBL. Enferm Infecc Microbiol Clin 25(Suppl 2):2–10. (In Spanish.)
3. Crandon JL, Nicolau DP. 2015. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother 59: 2688–2694. https://doi.org/10.1128/AAC.00033-15.
4. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 51: 1481–1486. https://doi.org/10.1128/AAC.00752-06.
5. Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. 2015. Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo--lactamase (VIM) in a murine thigh infection model. Antimicrob Agents Chemother 59:7145–7147. https://doi.org/10.1128/AAC.00794-15.
6. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
7. U.S. Food and Drug Administration. Microbiology review. Drug approval package: Avycaz. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000MicroR.pdf. Updated March 12, 2015. Accessed 26 January 2016.
8. Borgonovi M, Miossec C, Lowther J. 2007. The Efficacy of ceftazidime combined with NXL104, a novel -lactamase inhibitor, in a mouse model of kidney infections induced by -lactamase producing Enterobacteriaceae. Abstr Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany.
9. McGregor JC, Allen GP, Bearden DT. 2008. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther Clin Risk Manag 4:843–853. https://doi.org/10.2147/TCRM.S3426.
10. Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ. 2016. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother 71:2014–2021. https://doi.org/10.1093/jac/dkw053.
11. Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W. 2017. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis 17:404. https://doi.org/10.1186/s12879-017-2502-x.
12. Sevgi DY, Gunduz A, Sahin AM, Derin O, Konuklar AS, Oncul A, Uzun N, Sonmez E. 2014. Ertapenem for the treatment of complicated urinary tract infections caused by extended-spectrum -lactamase-producing bacteria: a case series report. Dis Mol Med 2:7–11. https://doi.org/10.5455/dmm.20140416054553.
13. Fong JJ, Rosé L, Radigan EA. 2012. Clinical Outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum -lactamase producing Gram-negative bacteria. Ann Pharmacother 46: 347–352. https://doi.org/10.1345/aph.1Q473.
14. Eagle H, Fleischman R, Musselman AD. 1950. The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms. Ann Intern Med 33:544–571. https://doi.org/10.7326/0003-4819-33-3-544.